RU2013132085A - METHOD FOR TREATING PATIENTS WITH RHEUMATOID ARTHRITIS - Google Patents
METHOD FOR TREATING PATIENTS WITH RHEUMATOID ARTHRITIS Download PDFInfo
- Publication number
- RU2013132085A RU2013132085A RU2013132085/14A RU2013132085A RU2013132085A RU 2013132085 A RU2013132085 A RU 2013132085A RU 2013132085/14 A RU2013132085/14 A RU 2013132085/14A RU 2013132085 A RU2013132085 A RU 2013132085A RU 2013132085 A RU2013132085 A RU 2013132085A
- Authority
- RU
- Russia
- Prior art keywords
- equal
- day
- less
- level
- time equal
- Prior art date
Links
Abstract
Способ лечения больных ревматоидным артритом, включающий одновременное комплексное применение лекарственных препаратов и лазерной терапии, отличающийся тем, что в качестве базисного противовоспалительного препарата применяют метотрексат подкожно в дозе 15 мг 1 раз в неделю, а также фолиевую кислоту внутрь по 5 мг в неделю, дополнительно назначают мовалис внутримышечно в дозе 15 мг 1 раз в сутки, лазерную терапию назначают дифференцированно, в зависимости от степени активности заболевания, степени выраженности эндотелиальной дисфункции, а именно фактора Виллебранда, уровня показателей активности системы гемостаза, а именно уровня активированного частичного тромбопластинового времени, протромбинового времени, тромбинового времени, антитромбина III, протеина С, при I степени активности заболевания, уровне активированного частичного тромбопластинового времени, равного и более 30,6±1,5 с, протромбинового времени, равного и более 19,2±0,9 с, тромбинового времени, равного и более 15,1±0,7 с, антитромбина III равного и более 92,8±7,6%, протеина С (НО), равного и более 0,92±0,02, фактора Виллебранда, равного и менее 108,9±9,6%, проводят 6-8 ежедневных процедур внутривенного лазерного облучения крови в первый день в течение 15 мин длиной волны 0,365 мкм, на следующий день в течение 5 мин длиной волны 0,405 мкм, мощностью излучения на конце световода 1,5-2,0 мВт, в непрерывном режиме излучения, процедуры чередуют через день, при II и III степени активности заболевания, уровне активированного частичного тромбопластинового времени, равного и менее 22,2±5,5 с, протромбинового времени, равного и менее 12,8±1,7 с, тромбинового времени, равного и менее 11,2±0,9 с, антитромA method of treating patients with rheumatoid arthritis, including the simultaneous combined use of drugs and laser therapy, characterized in that methotrexate is used subcutaneously as a basic anti-inflammatory drug at a dose of 15 mg once a week, and folic acid inside is administered at a dose of 5 mg per week, additionally prescribed moval intramuscularly at a dose of 15 mg once a day, laser therapy is prescribed differentially, depending on the degree of activity of the disease, the severity of endothelial dysfunction, namely von Willebrand factor, the level of indicators of the activity of the hemostatic system, namely the level of activated partial thromboplastin time, prothrombin time, thrombin time, antithrombin III, protein C, with degree I of disease activity, the level of activated partial thromboplastin time equal to and more than 30.6 ± 1 , 5 s, prothrombin time equal to and more than 19.2 ± 0.9 s, thrombin time equal to and more than 15.1 ± 0.7 s, antithrombin III equal to and more than 92.8 ± 7.6%, protein C (BUT), equal to and more than 0.92 ± 0.02, von Willebrand factor, equal and less than 108.9 ± 9.6%, 6-8 daily procedures of intravenous laser blood irradiation are carried out on the first day for 15 minutes at a wavelength of 0.365 microns, the next day for 5 minutes at a wavelength of 0.405 microns, radiation power at the end optical fiber 1.5-2.0 mW, in continuous radiation mode, the procedures alternate every other day, at the II and III degree of disease activity, the level of activated partial thromboplastin time equal to and less than 22.2 ± 5.5 s, prothrombin time equal to and less than 12.8 ± 1.7 s, thrombin time equal to and less than 11.2 ± 0.9 s, antithrom
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013132085/14A RU2537889C1 (en) | 2013-07-10 | 2013-07-10 | Method of treating patients with rheumatoid arthritis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013132085/14A RU2537889C1 (en) | 2013-07-10 | 2013-07-10 | Method of treating patients with rheumatoid arthritis |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2537889C1 RU2537889C1 (en) | 2015-01-10 |
RU2013132085A true RU2013132085A (en) | 2015-01-20 |
Family
ID=53280708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013132085/14A RU2537889C1 (en) | 2013-07-10 | 2013-07-10 | Method of treating patients with rheumatoid arthritis |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2537889C1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2696285C1 (en) * | 2018-05-15 | 2019-08-01 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Method of vasomotor endothelial dysfunction correction and arterial rigidity in patients with rheumatoid arthritis |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1752414A1 (en) * | 1990-06-27 | 1992-08-07 | Московский медицинский стоматологический институт им.Н.А.Семашко | Method of rheumatic arthritis treatment |
UA17548U (en) * | 2006-08-02 | 2006-09-15 | Olena Petrivna Dudyk | Method for treating deep caries and pulpitis using material based on bioactive ceramics |
-
2013
- 2013-07-10 RU RU2013132085/14A patent/RU2537889C1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2537889C1 (en) | 2015-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Van der Hagen et al. | Autologous platelet‐derived growth factors (platelet‐rich plasma) as an adjunct to mucosal advancement flap in high cryptoglandular perianal fistulae: a pilot study | |
Bennardo et al. | Autologous platelet‐rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication‐related osteonecrosis of the jaw | |
Buser et al. | Inflammatory response of intervertebral disc cells is reduced by fibrin sealant scaffold in vitro | |
Helissey et al. | Chronic inflammation and radiation-induced cystitis: molecular background and therapeutic perspectives | |
RU2020136589A (en) | TREATMENT OF DEGENERATIVE JOINT DISEASES | |
Dernek et al. | Efficacy of combined ozone and platelet-rich-plasma treatment versus platelet-rich-plasma treatment alone in early stage knee osteoarthritis | |
RU2015117539A (en) | DIAGNOSTICS, PREVENTION AND TREATMENT OF JOINT DISEASES | |
RU2013123646A (en) | COMBINED COMPOSITION | |
Kikuchi et al. | Recurrence of hydroxyurea-induced leg ulcer after discontinuation of treatment | |
EA200600921A1 (en) | METHODS AND COMPOSITIONS WITH THE USE OF TALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCER AND OTHER DISEASES | |
Afradi et al. | Treatment of 100 chronic thalassemic leg wounds by plasma‐rich platelets | |
Genah et al. | Effect of NIR laser therapy by MLS-MiS source on fibroblast activation by inflammatory cytokines in relation to wound healing | |
Al‐Hallak et al. | Efficacy of injectable platelet‐rich fibrin in the treatment of symptomatic oral lichen planus | |
RU2013132085A (en) | METHOD FOR TREATING PATIENTS WITH RHEUMATOID ARTHRITIS | |
Zhao et al. | M2 macrophage polarization: a potential target in pain relief | |
EA201390950A1 (en) | HOMOGENEOUS PHARMACEUTICAL ORAL DOSAGE FORMS CONTAINING LERKANIDIPIN AND ENALAPRIL OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS TOGETHER WITH ORGANIC ACID | |
Inchingolo et al. | MRONJ treatment strategies: a systematic review and two case reports | |
RU2009101026A (en) | APPLICATION OF THYMOSINE-ALPHA-1 FOR PRODUCING A MEDICINE FOR TREATING MALIGNANT MELANOMA IN STAGE IV | |
Saraf et al. | Serial intraarticular injections of growth factor concentrate in knee osteoarthritis: a placebo controlled randomized study | |
MacLaughlin et al. | Effect of intermittent hyperoxia on stem cell mobilization and cytokine expression | |
Chiran et al. | Intravenous laser blood irradiation and tocilizumab in a patient with juvenile arthritis | |
CO6331430A2 (en) | PHARMACEUTICAL COMPOSITION INCLUDING THE COMBINATION OF A KETOROLACO SALT AND VITAMINS OF COMPLEX B FOR THE TREATMENT OF NEURALGIA | |
RU2537031C2 (en) | Method of treating cystitis | |
RU2585097C1 (en) | Method of treating chronic pancreatitis | |
Kamangar et al. | CUTIS Do Not Copy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160711 |